Three-dimensional (3D) bioprinting is bringing about a paradigm shift in personalised medicine in the 21st century. According to a report by Mordor Intelligence (1), the global 3D bioprinting market was valued at USD 724.17 million in 2020 and is expected to reach USD 2398.27 million by 2026, growing at a CAGR of 21.91% over the forecast period (2021-2026). It has been predicted that the Asia-Pacific region has the highest scope for growth due to present demands (2).
There’s presently an overwhelming demand for donated organs. However, it takes a long . . .
This exclusive content is reserved for our valued members. Kindly log in or sign up to enjoy full access and delve into the complete article.
